London-based healthtech startup ZOE has secured $15M (€13.8M) in funding from Coefficient Capital. Co-founder and CEO Jonathan Wolf stated that the investment, though unsolicited, will help ZOE expand its US operations and improve public health by providing personalized dietary guidance. The funding will be used to scale operations, enhance services, and reach a broader audience in the US.

UK wellness start-up Zoe secures $15m investment to expand in US.

Zoe, a nutrition company based in London, is expanding its presence in the United States after raising $15 million in a Series B extension.Here’s how it works: Zoe sends customers at-home testing materials to collect blood or feces to test blood fat, blood sugar, and gut microbiome health. Following those results, the company scores every food (on a scale from 0 to 100), so people can make better choices of what to eat. Zoe’s nutrition-tracking programs includes glucose monitoring. (Image credit: Zoe)Image Credits: Zoe / Along the way, Zoe teaches users how to swap, add, and combine foods so you can eat in the best way for your body. For example, it might advise a user to swap out toast with peanut butter, bananas, and sliced almonds for toast with cream cheese, avocado, and chia seeds. It also tracks their progress with continued gut microbiome testing.The new investment comes from the U.S.-based investment company Coefficient Capital and gives Zoe $118 million in total funding to date, including a £25 million ($30 million at the time) raise in 2022.The latest raise follows the completion of a randomized controlled trial published in Nature Medicine in May 2024. The trial looked at the effects of personalized nutrition on cardiometabolic health